Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phillip L Lieberman

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
The American Journal of Medicine|January 4, 2014
Recognition and first-line treatment of anaphylaxisPhillip L Lieberman
Immunology and Allergy Clinics of North America|April 17, 2016
Nonallergic Rhinitis: TreatmentPhillip L Lieberman, Peter Smith
The American Journal of Medicine|August 7, 2007
Office-based management of allergic rhinitis in adultsJeffrey M Lehman, Phillip L Lieberman
The American Journal of Medicine|January 4, 2014
Anaphylaxis: underdiagnosed, underreported, and undertreatedDavid A Sclar, Phillip L Lieberman
Allergy and Asthma Proceedings|June 5, 2003
Azelastine nasal spray: a review of pharmacology and clinical efficacy in allergic and nonallergic rhinitisPhillip L Lieberman, Russell A Settipane
Clinical Allergy and Immunology|March 27, 2004
Drug allergens, haptens, and anaphylatoxinsVivian P Hernandez-Trujillo, Phillip L Lieberman, Badrul A Chowdhury
The Journal of Allergy and Clinical Immunology|March 8, 2017
ReplyPhillip L Lieberman, Dale T Umetsu, Gillis J Carrigan, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|April 10, 2017
An analysis of anaphylaxis cases at a single pediatric emergency department during a 1-year periodChristopher D Wright, Mindy Longjohn, Phillip L Lieberman, et al.
The Journal of Allergy and Clinical Immunology|May 30, 2016
Anaphylactic reactions associated with omalizumab administration: Analysis of a case-control studyPhillip L Lieberman, Dale T Umetsu, Gillis J Carrigan, et al.
The Journal of Allergy and Clinical Immunology|August 12, 2017
Anaphylaxis associated with omalizumab administration: Risk factors and patient characteristicsPhillip L Lieberman, Ilisten Jones, Richa Rajwanshi, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
The American Journal of Medicine|January 4, 2014
Recognition and first-line treatment of anaphylaxisPhillip L Lieberman
Immunology and Allergy Clinics of North America|April 17, 2016
Nonallergic Rhinitis: TreatmentPhillip L Lieberman, Peter Smith
The American Journal of Medicine|August 7, 2007
Office-based management of allergic rhinitis in adultsJeffrey M Lehman, Phillip L Lieberman
The American Journal of Medicine|January 4, 2014
Anaphylaxis: underdiagnosed, underreported, and undertreatedDavid A Sclar, Phillip L Lieberman
Allergy and Asthma Proceedings|June 5, 2003
Azelastine nasal spray: a review of pharmacology and clinical efficacy in allergic and nonallergic rhinitisPhillip L Lieberman, Russell A Settipane
Clinical Allergy and Immunology|March 27, 2004
Drug allergens, haptens, and anaphylatoxinsVivian P Hernandez-Trujillo, Phillip L Lieberman, Badrul A Chowdhury
The Journal of Allergy and Clinical Immunology|March 8, 2017
ReplyPhillip L Lieberman, Dale T Umetsu, Gillis J Carrigan, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|April 10, 2017
An analysis of anaphylaxis cases at a single pediatric emergency department during a 1-year periodChristopher D Wright, Mindy Longjohn, Phillip L Lieberman, et al.
The Journal of Allergy and Clinical Immunology|May 30, 2016
Anaphylactic reactions associated with omalizumab administration: Analysis of a case-control studyPhillip L Lieberman, Dale T Umetsu, Gillis J Carrigan, et al.
The Journal of Allergy and Clinical Immunology|August 12, 2017
Anaphylaxis associated with omalizumab administration: Risk factors and patient characteristicsPhillip L Lieberman, Ilisten Jones, Richa Rajwanshi, et al.
Pageof 2